JMP Securities Downgrades Athira Pharma to Market Perform
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has downgraded Athira Pharma from Market Outperform to Market Perform, indicating a less optimistic view on the company's stock performance.
September 04, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JMP Securities analyst Jason Butler has downgraded Athira Pharma from Market Outperform to Market Perform, suggesting a more cautious outlook on the stock.
The downgrade from Market Outperform to Market Perform by JMP Securities indicates a shift to a more neutral stance on Athira Pharma's stock. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the analyst's revised outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100